Home > Products > Antibodies > Biosimilars

Research Grade Varlilumab (HB796016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HB796016
DescriptionVarlilumab is a fully human monoclonal antibody (mAb) that targets CD27, a critical molecule in the activation pathway of lymphocytes. Like CD40, CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and anti-tumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHuman
IsotypeIgG1-kappa
Expression systemMammalian Cells
ClonalityMonoclonal
TargetCD27L receptor, TNFRSF7, T14, CD27 antigen, Tumor necrosis factor receptor superfamily member 7, CD27, T-cell activation antigen CD27
Concentration2mg/ml
Endotoxin levelPlease contact the lab for this information.
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G, purified from cell culture supernatant.
AccessionP26842
FormLiquid
Storage buffer0.01M PBS,pH7.4.
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -88°C.
Alternate Names1F5,CDX-1127,CAS:1393344-72-3
BackgroundVarlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity.
NoteFor research use only. Not for use in clinical or therapeutic applications.
Images
References

Recommendation